PDIA5 and prostate adenocarcinoma: Using pan-cancer samples, we detected the PDIA5 expression in laryngeal squamous cell carcinoma (LSCC), THCA, BLCA, urinary tract urothelial carcinoma (UTUC), LGG, GBM, UCEC, CESC, ovarian serous papillary cystadenocarcinoma (OPV), OV, penis squamous cell carcinoma (PSCC), TGCT, and PRAD.